ONSOLIS (fentanyl citrate) by Hikma is analgesia. First approved in 2009.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
ONSOLIS is a buccal film formulation of fentanyl citrate, a potent opioid analgesic approved in 2009. It delivers fentanyl through the oral mucosa for rapid systemic absorption, providing analgesia in opioid-tolerant patients. The buccal route enables faster onset and avoids first-pass metabolism compared to oral administration.
Product is approaching loss of exclusivity with limited remaining patent life; team may be consolidating or focusing on defensive strategies rather than expansion.
analgesia.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
Worked on ONSOLIS at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Working on ONSOLIS offers limited career advancement given its approaching LOE and minimal linked job openings. Roles are primarily focused on defensive brand management, maintaining market share, and preparing for generic competition rather than growth initiatives.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo